Nucleic acid molecules encoding antibodies that bind cell-associated CA 125/O772P
AssigneePurdue Pharma L.P.
InventorsEarl F. Albone, Daniel A. Soltis
Life of this patent
Estimating the term…
Loading patent…
AssigneePurdue Pharma L.P.
InventorsEarl F. Albone, Daniel A. Soltis
Estimating the term…
The present invention provides antibodies, and antigen-binding fragments of antibodies, fusion polypeptides and analogs that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides. The present invention further provides methods of preventing, managing, treating or ameliorating one or more symptoms associated with a CA 125/O772P-related disorder. In particular, the present invention provides methods of preventing, managing, treating, or ameliorating one or more symptoms associated with a cell proliferative disorder, such as cancer, e.g., ovarian cancer. The present invention still further provides methods for diagnosing a CA 125/O772P-related disorder or predisposition to developing such a disorder, as well as methods for identifying antibodies, and antigen-binding fragments of antibodies, that preferentially bind cell-associated CA 125/O772P polypeptides relative to shed CA 125/O772P polypeptides.
An isolated nucleic acid molecule comprising a nucleotide sequence that encodes a variable chain region selected from the group consisting of SEQ ID NOs:27, 28, 31, 32, 33, 34, 53, 54 55, and 56.
Dependencies are inferred from the claim text.